MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Omeros Corporation Net Debt 2011-2026 | OMER
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Omeros Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84 M | 167 M | -1.8 M | 304 M | 213 M | 229 M | 213 M | 198 M | 160 M | 120 M | 48.5 M | 32.4 M | 19.1 M | 39.4 M | 15.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 304 M | -1.8 M | 123 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
41 B | $ 350.13 | 2.98 % | $ 188 B |  USA |
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.29 B | $ 12.73 | 3.33 % | $ 3.99 B | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
argenx SE
ARGX
|
-89.9 M | $ 783.17 | 2.32 % | $ 25 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
-32.7 M | $ 1.48 | 8.82 % | $ 394 M |  Britain |
 |
Applied Therapeutics
APLT
|
-49.4 M | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
65.3 M | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
9.86 B | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 91.64 | 2.25 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.82 | 1.6 % | $ 9.19 B |  Australia |
 |
Burford Capital Limited
BUR
|
-135 M | $ 4.62 | 1.54 % | $ 742 M | Britain |
 |
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-19.9 M | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-188 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 3.05 | 0.66 % | $ 6.64 B | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-76.6 M | $ 3.05 | -0.5 % | $ 306 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | USA |
 |
Cerus Corporation
CERS
|
-6.9 M | $ 1.93 | 4.62 % | $ 368 M | USA |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-127 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-3.34 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-12.8 M | $ 2.83 | 2.91 % | $ 7.38 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-65.3 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | Germany |
 |
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.73 | 3.59 % | $ 203 M | USA |